• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Once-a-week cagrilintide is effective for weight management in overweight and obese patients

byNeel MistryandTeddy Guo
December 21, 2021
in Chronic Disease, Endocrinology, Gastroenterology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. By week 26, cagrilintide resulted in significantly increased weight reduction compared to liraglutide and placebo.

2. Gastrointestinal adverse events, such as nausea, constipation, and diarrhea, were more common in the cagrilintide group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Cagrilintide is a synthetic amylin analogue used to induce satiety in patients. Currently, most guidelines recommend lifestyle interventions as first line for weight management. Pharmacotherapy is limited to only a few drugs, including GLP-1 receptor agonists. With obesity becoming a widespread problem, exploring alternative options for obesity and weight management is key. This randomized controlled trial aimed to assess the efficacy, safety, and tolerability of cagrilintide 0.3-4.5 mg, compared to liraglutide 3.0 mg and placebo, in patients with a body-mass index (BMI) in the overweight and obesity ranges. The primary outcome was the mean change in bodyweight from baseline to week 26 after randomization, while key secondary outcomes included change in waist circumference, lipid levels, and glycemic control. According to results, patients in the cagrilintide group reported significantly greater reduction in bodyweight compared to liraglutide and placebo at week 26.

Click to read the study in The Lancet

Relevant Reading: Once-Weekly Semaglutide in Adults with Overweight or Obesity

In-depth [randomized controlled trial]: Between Mar 1 and Aug 19, 2019, 886 patients were assessed for eligibility across 57 sites in 10 countries. Included were those ≥18 years of age with BMI ≥27 kg/m2, with hypertension or dyslipidemia, and no diabetes. Altogether, 706 patients were included (100-102 each to cagrilintide 0.3, 0.6, 1.2, 2.4, or 4.5 mg, 99 to liraglutide 3.0 mg, and 101 to placebo) in the final analysis. The primary outcome of bodyweight reduction was greater among patients in the cagrilintide group than placebo (estimated treatment difference [ETD] range 3.0%-7.8%, p<0.001). A similar pattern was noticed for cagrilintide 4.5 mg versus liraglutide 3.0 mg (10.8% vs. 9.0%, ETD 1.8%, p=0.03). Patients across all cagrilintide doses reported similar rates of adverse gastrointestinal events compared to liraglutide, including nausea, constipation, and diarrhea. However, when comparing cagrilintide 0.3-4.5 mg to placebo, a greater number of GI adverse events (41%-63% vs. 32%) were noted. Overall, findings from this study suggest that cagrilintide may be effective in the management of overweight and obese patients.

RELATED REPORTS

Subsidization of supermarkets may help reduce obesity risk in children

Wellness Check: Nutrition

Review suggests mixed evidence for relationship between food insecurity and childhood obesity

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: BMI overweightbody mass index (BMI)cagrilintidedyslipidemialiraglutideobesityoverweightweight lossweight management
Previous Post

Quantitative flow ratio-guided coronary intervention reduces the rate of major cardiac events compared to visual angiography

Next Post

#VisualAbstract: Pericardiotomy after cardiac surgery may reduce the incidence of postoperative atrial fibrillation

RelatedReports

Meeting families, demographic information affect child abuse work-up
Pediatrics

Subsidization of supermarkets may help reduce obesity risk in children

June 27, 2022
Provision of medically-tailored meals linked with lower admissions and medical spending
Wellness

Wellness Check: Nutrition

June 23, 2022
Improved glycemic control in type 1 diabetics on very low-carbohydrate diets
Cardiology

Review suggests mixed evidence for relationship between food insecurity and childhood obesity

June 14, 2022
Sleep duration inversely related to childhood type 2 diabetes risk makers
Cardiology

Time restricted eating not more beneficial than daily calorie restriction

May 13, 2022
Next Post
#VisualAbstract: Pericardiotomy after cardiac surgery may reduce the incidence of postoperative atrial fibrillation

#VisualAbstract: Pericardiotomy after cardiac surgery may reduce the incidence of postoperative atrial fibrillation

Systematic cardiac screening may not be required amongst junior competitive athletes  

#VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males

#VisualAbstract: Neoadjuvant chemotherapy plus surgery improves overall survival compared to surgery alone in locally advanced esophageal cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.